We Are A Global Team Dedicated To Improve The Lives Of Patients With Fragile X Syndrome And Autism Spectrum Disorderour Work Spans Three Decades Of Research In Neuroscience And Intellectual Disabilitiesthemglur Theory Of Fragile Xproposed By Mit Professor Mark Bear And Collaborators In 2004 Is Widely Considered To Be A Key Conceptual Breakthroughand Laid The Foundation For Development Of Disease Modifying Therapies For Treatment Of Fragile X Syndrome And Autism Spectrum Disorderallos Pharma Is Committed To Develop And Market The First Approved Therapy In Fragile X Syndrome The Name Allos Pharma Is Derived Fromallisticmeaning Not Autistic
